FDMT vs REGN: Which Stock is Better?
Side-by-side comparison of 4D Molecular Therapeutics Inc and Regeneron Pharmaceuticals Inc in 2026
FDMT
4D Molecular Therapeutics Inc
$8.46
REGN
Regeneron Pharmaceuticals Inc
$766.66
Key Metrics Comparison
| Metric | FDMT | REGN | Winner |
|---|---|---|---|
| Market Cap | $533.07M | $83.60B | REGN |
| P/E Ratio | N/A | 19.05 | REGN |
| EPS (TTM) | $N/A | $41.52 | REGN |
| Revenue Growth | 29.0% | 0.0% | FDMT |
| Gross Margin | -148295.8% | 44.6% | REGN |
Analyze FDMT
Full quant analysis
Analyze REGN
Full quant analysis
Analyze Each Stock
Frequently Asked Questions
Is FDMT or REGN a better investment?
Comparing FDMT and REGN: 4D Molecular Therapeutics Inc has a market cap of $533.07M while Regeneron Pharmaceuticals Inc has $83.60B. Both companies have their strengths - use our detailed metrics comparison to make an informed decision.
What is the difference between FDMT and REGN?
FDMT (4D Molecular Therapeutics Inc) and REGN (Regeneron Pharmaceuticals Inc) differ in valuation, growth rates, and profitability metrics. Our comparison shows which company leads in each category.
Which stock has better value: FDMT or REGN?
Based on P/E ratios, compare detailed valuation metrics on our dashboard.
Which is growing faster: FDMT or REGN?
FDMT has higher revenue growth at 29.0% vs 0.0% for REGN.
Which company is more profitable: FDMT or REGN?
Regeneron Pharmaceuticals Inc (REGN) has higher gross margins at 44.6% compared to -148295.8% for FDMT.
Which is the larger company: FDMT or REGN?
Regeneron Pharmaceuticals Inc (REGN) is larger with a market cap of $83.60B compared to $533.07M for FDMT.
Should I buy FDMT or REGN in 2026?
Both FDMT and REGN have investment merit. FDMT trades at $8.46 while REGN trades at $766.66. Consider your investment goals, risk tolerance, and portfolio diversification before deciding. Our AI analysis tools can provide personalized insights.
What are the key differences between FDMT and REGN stock?
Key differences: Market Cap ($533.07M vs $83.60B), P/E Ratio (N/A vs 19.0x), Revenue Growth (29.0% vs 0.0%), Gross Margin (-148295.8% vs 44.6%).